AbbVie (ABBV) Change in Cash (2012 - 2026)
AbbVie (ABBV) posted quarterly Change in Cash of $4.2 billion for Q1 2026, up 1292.55% year-over-year from $298.9 million in Q1 2025, and up 1140.5% quarter-over-quarter from -$400.0 million in Q4 2025.
AbbVie (ABBV) Change in Cash (2012 - 2026) Analysis & Trends
AbbVie (ABBV) has reported Change in Cash for 15 consecutive years, with $4.2 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Cash rose 1292.55% year-over-year to $4.2 billion; the TTM figure through Mar 2026 stood at $4.2 billion (up 132.7% YoY), while the FY2025 annual figure was -$295.0 million, up 95.95% from the prior year.
- Change in Cash rose to $4.2 billion in Q1 2026 per ABBV's latest filing, from -$400.0 million in the prior quarter.
- Across five years, Change in Cash topped out at $5.3 billion in Q1 2024 and bottomed at -$5.9 billion in Q3 2024.
- Historically, Change in Cash has averaged -$20.9 million across 5 years, with a median of -$400.0 million in 2025.
- Annual changes were most pronounced in 2022 — Change in Cash sank 379.33% — and 2026, when it soared 1292.55%.
- AbbVie's Change in Cash stood at -$2.6 billion in 2022, then surged by 82.02% to -$473.0 million in 2023, then tumbled by 266.38% to -$1.7 billion in 2024, then jumped by 76.92% to -$400.0 million in 2025, then jumped by 1140.5% to $4.2 billion in 2026.
- Business Quant data shows ABBV's Change in Cash at $4.2 billion in Q1 2026, -$400.0 million in Q4 2025, and -$838.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Cash (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | -1.27 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | -2.82 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 1.49 Bn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 739.00 Mn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.95 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | -4.45 Bn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -727.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -14.32 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2.82 Bn |
| Mar 31, 2026 | 4.16 Bn |
| Dec 31, 2025 | -400.00 Mn |
| Sep 30, 2025 | -838.00 Mn |
| Jun 30, 2025 | 1.29 Bn |
| Mar 31, 2025 | -349.00 Mn |
| Dec 31, 2024 | -1.73 Bn |
| Sep 30, 2024 | -5.87 Bn |
| Jun 30, 2024 | -4.94 Bn |
| Mar 31, 2024 | 5.25 Bn |
| Dec 31, 2023 | -473.00 Mn |
| Sep 30, 2023 | 4.53 Bn |
| Jun 30, 2023 | 2.05 Bn |
| Mar 31, 2023 | -2.49 Bn |
| Dec 31, 2022 | -2.63 Bn |
| Sep 30, 2022 | 3.31 Bn |
| Jun 30, 2022 | 2.42 Bn |
| Mar 31, 2022 | -3.65 Bn |
| Dec 31, 2021 | -2.44 Bn |
| Sep 30, 2021 | 3.64 Bn |